Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 6, 2015, Pages 3399-3405

  Dooley, Kelly E ^a   Savic, Radojka M ^b   Park, Jeong Gun ^c   Cramer, Yoninah ^c   Hafner, Richard ^d   Hogg, Evelyn ^e   Janik, Jennifer ^f   Marzinke, Mark A ^a   Patterson, Kristine ^g   Benson, Constance A ^h   Hovind, Laura ^f   Dorman, Susan E ^a   Haas, David W ⁱ  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^f FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^g UNIVERSITY OF NORTH CAROLINA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMYCIN; RIFAPENTINE; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADULT; AGED; ANGIONEUROTIC EDEMA; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BRONCHOSPASM; CHILL; CLINICAL ARTICLE; CONJUNCTIVITIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG ABSORPTION; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; FEVER; GENOTYPE; HEADACHE; HUMAN; HYPOTENSION; LIPID DIET; LYMPHOCYTOPENIA; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLING; STEADY STATE; URTICARIA; VOMITING; WEAKNESS; ADOLESCENT; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG ADMINISTRATION; MIDDLE AGED; NORMAL HUMAN; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEALTHY VOLUNTEERS; HUMANS; MALE; MIDDLE AGED; RIFAMPIN; YOUNG ADULT;

EID: 84929643043     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05128-14     Document Type: Article

References (24)

1. World Health Organization. 2014. Global tuberculosis report 2014. Report WHO/HTM/TB/2014.08. World Health Organization, Geneva, Switzerland.
2. Jayaram R, Gaonkar S, Kaur P, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharat S, Shandil RK, Kantharaj E, Balasubramanian V. 2003. Pharmacokinetics-pharmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 47:2118-2124. http://dx.doi.org/10.1128/AAC.47.7.2118-2124.2003.
3. Boeree MJ, Plemper van Balen G, Aarnoutse RA. 2011. High-dose rifampicin: how do we proceed? Int J Tuberc Lung Dis 15:1133. http://dx.doi.org/10.5588/ijtld.11.0113,10.5588/ijtld.11.0198.
4. th Conf Retrovir Opportunist Infect, Atlanta, GA.
5. Diacon AH, Patientia RF, Venter A, van Helden PD, Smith PJ, McIlleron H, Maritz JS, Donald PR. 2007. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob Agents Chemother 51:2994-2996. http://dx.doi.org/10.1128/AAC.01474-06.
6. Rosenthal IM, Zhang M, Williams KN, Peloquin CA, Tyagi S, Vernon AA, Bishai WR, Chaisson RE, Grosset JH, Nuermberger EL. 2007. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 4:e344. http://dx.doi.org/10.1371/journal.pmed.0040344.
7. Rosenthal IM, Tasneen R, Peloquin CA, Zhang M, Almeida D, Mdluli KE, Karakousis PC, Grosset JH, Nuermberger EL. 2012. Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother 56:4331-4340. http://dx.doi.org/10.1128/AAC.00912-12.
8. Zhang M, Li SY, Rosenthal IM, Almeida DV, Ahmad Z, Converse PJ, Peloquin CA, Nuermberger EL, Grosset JH. 2011. Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. Am J Respir Crit Care Med 183:1254-1261. http://dx.doi.org/10.1164/rccm.201012-1949OC.
9. Dooley KE, Bliven-Sizemore EE, Weiner M, Lu Y, Nuermberger EL, Hubbard WC, Fuchs EJ, Melia MT, Burman WJ, Dorman SE. 2012. Safety and pharmacokinetics of escalating daily doses of rifapentine, an antituberculosis drug, in healthy volunteers. Clin Pharmacol Ther 91:881-888. http://dx.doi.org/10.1038/clpt.2011.323.
10. Dorman SE, Goldberg S, Stout JE, Muzanyi G, Johnson JL, Weiner M, Bozeman L, Heilig CM, Feng PJ, Moro R, Narita M, Nahid P, Ray S, Bates E, Haile B, Nuermberger EL, Vernon A, Schluger NW, Tuberculosis Trials Consortium. 2012. Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the Tuberculosis Trials Consortium. J Infect Dis 206:1030-1040. http://dx.doi.org/10.1093/infdis/jis461.
11. Zvada SP, Van Der Walt JS, Smith PJ, Fourie PB, Roscigno G, Mitchison D, Simonsson US, McIlleron HM. 2010. Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers. Antimicrob Agents Chemother 54:3390-3394. http://dx.doi.org/10.1128/AAC.00345-10.
12. Division of AIDS. 2011. Table for grading the severity of adult and pediatric adverse events, version 1.0. Division of AIDS, National Institutes of Health, Bethesda, MD.
13. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR, Jr, Chaisson RE, TB Trials Consortium PREVENT TB Study Team. 2011. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 365:2155-2166. http://dx.doi.org/10.1056/NEJMoa1104875.
14. Dorman SE, Savic RM, Goldberg S, Stout JE, Schluger N, Muzanyi G, Johnson JL, Nahid P, Hecker EJ, Heilig CM, Bozeman L, Feng PJ, Moro RN, MacKenzie W, Dooley KE, Nuermberger EL, Vernon A, Weiner M, Tuberculosis Trials Consortium. 2014. Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med 19:333-343. http://dx.doi.org/10.1164/rccm.201410-1843OC.
15. Chung JY, Cho JY, Yu KS, Kim JR, Oh DS, Jung HR, Lim KS, Moon KH, Shin SG, Jang IJ. 2005. Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 78:342-350. http://dx.doi.org/10.1016/j.clpt.2005.07.003.
16. Chigutsa E, Visser ME, Swart EC, Denti P, Pushpakom S, Egan D, Holford NH, Smith PJ, Maartens G, Owen A, McIlleron H. 2011. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob Agents Chemother 55:4122-4127. http://dx.doi.org/10.1128/AAC.01833-10.
17. Savic RM, Lu Y, Bliven-Sizemore E, Weiner M, Nuermberger E, Burman W, Dorman SE, Dooley KE. 2014. Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. Antimicrob Agents Chemother 58:3035-3042. http://dx.doi.org/10.1128/AAC.01918-13.
18. th Int Workshop Clin Pharmacol Tuberc Drugs.
19. Ruslami R, Ganiem AR, Dian S, Apriani L, Achmad TH, van der Ven AJ, Borm G, Aarnoutse RE, van Crevel R. 2013. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis 13:27-35. http://dx.doi.org/10.1016/S1473-3099(12)70264-5.
20. Owens JP, Fofana MO, Dowdy DW. 2013. Cost-effectiveness of novel first-line treatment regimens for tuberculosis. Int J Tuberc Lung Dis 17: 590-596. http://dx.doi.org/10.5588/ijtld.12.0776.
21. th Int AIDS Conf.
22. Centers for Disease Control and Prevention (CDC) and American Thoracic Society. 2003. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection - United States, 2003. MMWR Morb Mortal Wkly Rep 52:735-739. mm5231a4.
23. Grosset J, Leventis S. 1983. Adverse effects of rifampin. Rev Infect Dis 5(Suppl 3):S440-S450.
24. Martinez E, Collazos J, Mayo J. 1999. Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions. Medicine (Baltimore) 78:361-369.